The most frequent adverse effects are gastrointestinal and dose-related: Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort - Typically worst during dose escalation and often resolve or attenuate with continued treatment and slower titration
Adipocyte phospholipase A2 (AdPLA2) is implicated in adipocyte lipolysis, and it has been demonstrated that its suppression triggers higher lipolysis rates and higher energy expenditure (Jaworski et al., 2009)
Many patients tolerate fruit better earlier in the day when nausea risk is lower, or in the 2-3 days after weekly injections when appetite suppression is milder
Analysis of the STEP trials showed that less than 1% of weight loss came from side effects (nausea, vomiting)
Novo Nordisk said it remains confident in the benefit-risk profile of our GLP-1 medicines when used consistent with their indications and product labeling. But neither directly addressed a link between GLP-1 drugs and an altered sense of smell
The majority of the TEAEs were reported as mild, resolved by the end of the study and were assessed as probably or possibly related to study product by the investigator (Tables 4, 5, 6)
